Job Ratings - rate as often as your feeling about your job changes

02/06/25
industry:
company:
job rating:
2
3 semaglutide products account for around 70% of Novo Nordisk sales. This makes the company vulnerable, and considering dominant economic position of the company in Danish national economy, it brings a serious risk for the country. Yet the company continues to do sleepwalking dragging the happiest nation into a hole, particularly that peptide patents are not difficult to overcome. Counting on lousy competitors may not be the best strategy at all.
02/06/25
industry:
company:
job rating:
1
Cannot put sound strategy together. Even with competitors exposed, so vulnerable. Taking token initiatives described as assets to bring advanced research and discoveries, but hollow, Open book to competitors. Mismanagement of inner and outer talent and entrenchment of parochial interests.
02/05/25
industry:
company:
job rating:
1
Amgen works like a training ground to certain foreign individuals. Their own people who are already in hire them and since they are incapable they may be pushed out after some stay, but be able to use Amgen name to obtain a position in a smaller company. Many such examples exist. The industry penetration scheme.
02/04/25
industry:
company:
job rating:
1
The company uses various discriminatory practices, and it is enough to contact ex-employees or retirees to obtain information.
01/31/25
industry:
job title:
Executive Director
company:
job rating:
2
Micromanagement, beat people up and no strategic vision
01/31/25
industry:
company:
job rating:
1
Novo Nordisk internal consultants are combined into a small department and they often come from McKinsey, eg. are McKinsey dropouts. Company keeps them in high regards due to the reputation of that consulting company. Currently they try to dazzle coworkers at Novo by producing generalized reports with impressive McKinsey vocabulary, but using various AI bots and putting minimum effort into this work. Not much of value, though.
01/30/25
industry:
company:
job rating:
1
Internal consultants at Lilly are not up to the task. They are often moved from the positions of responsibility to consultancy due to mediocre performance. Their advice is of low value. Could be interesting how this compares to similar internal consulting positions performance in other companies, like at Novo.
01/30/25
industry:
company:
job rating:
1
Gilead should stop tinkering with DEI and bring on board capable people with deep and diversified experience, forming more posts like Internal Advisors or Internal Consultants. Some companies do this.
01/29/25
industry:
company:
job rating:
1
As many know and some experienced personally Amgen has a continuous improvement policy, but unfortunately it also involves personnel replacement. This is not necessarily "dead wood" cleaning, but a matter of policy. This brings mistrust, fear, uncertainty and volatility. Not to mention negative internal networking. Has additional effects like that some good people leave, and others avoid to join Amgen.
01/29/25
industry:
company:
job rating:
1
Kite got another executive from Amgen. This happened before. Some say this is due to geographical proximity, others that it is due to Amgen personnel rotation, and others that because Kite is in a perpetual systemic trouble. May be all of this and may be some parties getting desperate. To us the most worrying is that Kite is in trouble.
01/28/25
industry:
company:
job rating:
1
We watch in dismay how the company conducts acquisitions and collaborations. Throwing money into unworthy partners. It tells there are no M&A skills in organization, no good know how in-house to evaluate technical and scientific value combined with some lack of local skills. Too many general managers, not enough technology managers. But hey, the markets are booming and competitors are even worse.
01/26/25
industry:
company:
job rating:
1
Big news how successfully we can help gluttons. And what profits this would bring so stock went up. Really nothing to celebrate. Do we want to treat a patient?
01/26/25
industry:
company:
job rating:
1
Future is in treating the obese, who bring the problem on themselves. No one needs such pharma and the high cost that is involved. The industry becomes unethical. This can be seen since it attracts unethical people from around the world who either occupy big American pharma companies, or start their own so called pharma shops. This could be only restricted by radical change of American Healthcare System. Not under the oligarchs. So the scum of the world, you are welcome.
01/25/25
industry:
company:
job rating:
2
Regeneron is full of foreign industrial spies
01/23/25
industry:
company:
job rating:
1
Having many Advisors on board but the internal strategy lacks depth and sounds sometimes amateurish and half-baked. Opposite to what Novo is trying by inviting McKinsey and other heavy weights. Strategy is still old fashioned pharma preoccupied with daily grind.
01/20/25
industry:
company:
job rating:
2
The image part, on surface all looks great, including token DEI images of happy workforce. Inside there is nationalism, collusion with own government, cronyism and even discrimination. Boasting wealth and comparing to budget of own government happened. Reason to work together. Many managers have come from local industries or government branches with no experience in biopharma. Too many managers, often covering narrow or artificial divisions. Poor collaboration with overseas operations. Superficial push towards modernization and giving this great publicity. Often can beat competition since apparently they are even in a worse shape. With oversized workforce company can play social public relations game offering employees long family leave benefits. This is possible since there are no serious domestic competitors and government tolerates and likes such monopoly if it keeps part of population happy. Often making wrong decisions in M&A or collaborations that come from excessive profits and available funding.
01/20/25
industry:
company:
job rating:
2
Due to poor economic forecast, Merck would send some of his employees back home.
01/20/25
industry:
job rating:
2
Projected serious revenue decline makes layoffs certain in 2025.
01/20/25
industry:
company:
job rating:
1
No raises in sight in 2025, possibly layoffs. If any promotions, they will be as inflated titles. New layers of titles might be added. Salary reductions? Possibly not.
01/19/25
industry:
job rating:
1
At last JPM Conference in SF the wonderful management team demonstrated how they will rune the company. To the ground.

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.